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Chronic venous disease (CVD) is a multifactorial condition representing one of the most common 
disorders among populations of Western countries. The heritability of about 17% suggests genetic risk 
factors in CVD etiology. However, so far the genetic causes are unknown. We undertook the hitherto 
first genome-wide association study (GWAS) for CVD, analyzing more than 1.93 M SNPs in 4,942 
German individuals, followed by replication in two independent German data sets. The combined 
analysis of discovery and replication stages (2,269 cases and 7,765 controls) yielded robust associations 
within the two genes EFEMP1 and KCNH8 (rs17278665, rs727139 with P < 5 × 10−8), and suggestive 
association within gene SKAP2 (rs2030136 with P < 5 × 10−7). Association signals of rs17278665 and 
rs727139 reside in regions of low linkage disequilibrium containing no other genes. Data from the 
ENCODE and Roadmap Epigenomics projects show that tissue specific marks overlap with the variants. 
SNPs rs17278665 and rs2030136 are known eQTLs. Our study demonstrates that GWAS are a valuable 
tool to study the genetic component of CVD. With our approach, we identified two novel genome-wide 
significant susceptibility loci for this common disease. Particularly, the extracellular matrix glycoprotein 
EFEMP1 is promising for future functional studies due to its antagonistic role in vessel development and 
angiogenesis.
CVD is a complex venous pathology and defined as “morphological and functional abnormalities of the venous 
system of long duration manifested either by symptoms and/or signs indicating the need for investigation and/
or care”1. Prevalence of CVD in Germany and the United States was estimated at 31%2 and 29%2, respectively. 
The term CVD encompasses patients with primary varicose veins (PVV) and chronic venous insufficiency 
(CVI). According to the CEAP guidelines (Comprehensive Classification System for Chronic Venous Disorders), 
absence of visible or palpable signs of venous disease is classified as C0 whereas the presence of telangiectasia or 
reticular veins leads to C1 classification. Varicose veins are distinguished from reticular veins by a diameter of at 
least 3 mm so that PVV patients who have dilated subcutaneous veins (≥ 3 mm Ø) but no signs of edema or skin 
changes are classified as C2. Patients with CVI can be classified as either C3 (edema), C4 (skin changes without 
ulceration), C5 (healed venous ulcer) or C6 (active venous ulcer)3,4. Exemplary photos for C1 to C6 are shown in 
Fig. 1. CVD has a major socioeconomic impact. The financial burden of CVD treatment on the health-care sys-
tem is immense with an estimated cost of US$3 billion per year in the USA and up to 2% of the total health-care 
budget of all Western countries5,6. Despite the frequency of CVD and its considerably high impact on health-care 
budgets and on patients’ quality of life the underlying etiology and pathophysiology are still poorly understood. 
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Many factors may increase risk for CVD, including age, female gender, pregnancy, hormonal changes, obesity and 
standing occupation and predispose individuals to the dilatation, elongation and tortuosity of the saphenous vein 
and its tributaries7. In addition, a genetic component has been proposed for many years, supported by reports 
on familial clustering and twin studies8–10. The narrow-sense heritability (proportion of the phenotypic variance 
that is explained by additive genetic variance) of PVV and CVD has recently been estimated to equal 18.5% and 
17.3%, respectively, in a large sample of affected nuclear families from Germany4. These heritability estimates 
suggest the existence of susceptibility genes, necessitating large systematic association studies. So far, no disease 
association has been confirmed. To further our understanding of the genetic etiology of CVD, we undertook 
the hitherto first genome-wide association study (GWAS) for this multifactorial condition comprising 10,034 
individuals in total.
Results
To identify common variants that confer susceptibility to CVD, we performed genome-wide SNP genotyping 
of 323 unrelated German C2, C3 and C4 CVD cases and 4,619 healthy German control individuals employing 
Affymetrix SNP arrays (panel A, Supplementary Table 1). Principal component analysis supported European 
ancestry for all cases and controls (Methods, Supplementary Figure 1). To facilitate the analysis of the four 
data sets genotyped on different SNP chips and to increase the genomic coverage of our study by predicting 
untyped markers, SNP genotype imputation was performed. For imputation and subsequent statistical analysis, 
we used data sets that passed stringent quality control filters (Methods). In total, 1,934,349 quality-controlled 
autosomal-imputed SNP markers were available for association analysis (Supplementary Figure 2). Assuming 
a frequency of the disease-associated allele of at least 20% in controls, our screening panel had 79% power to 
detect a variant with an odds ratio of 1.3 or higher at the 0.001 significance level, which was the value used 
to define regions for attempting replication in a larger sample set. For stage one replication, we selected 70 
SNPs based on their P-value rankings in the discovery stage and support by other SNPs in linkage disequi-
librium (Methods, Supplementary Table 2). The replication sample of stage one consisted of 1,258 independ-
ent CVD cases and 1,925 controls from Germany (panel B, Supplementary Table 1). For stage two replication 
analysis, we selected three SNPs that replicated at a significance level of P < 0.05/70 = 7.14 × 10−4 (based on 
Bonferroni correction) in replication stage one for TaqMan® genotyping (Supplementary Table 3) in an addi-
tional German panel comprising 688 CVD cases and 1,221 control individuals (panel C, Supplementary Table 1). 
We used a significance level of 7.14 × 10−4 for the statistical association analysis in the replication panels (panel 
B and C; Supplementary Table 1) based on Bonferroni correction (Methods). All three SNPs were signifi-
cant in a meta-analysis of the combined replication data (panel B and C) after adjusting for multiple testing 
(PRepl1&2 = 2.59 × 10−5 for rs17278665; PRepl1&2 = 3.39 × 10−8 for rs727139; PRepl1&2 = 6.84 × 10−5 for rs2030136; 
Table 1). In a combined meta-analysis of the discovery and replication samples (2,269 CVD cases and 7,765 con-
trols) SNPs rs17278665 (Pcombined = 1.74 × 10−8) and rs727139 (Pcombined = 5.42 × 10−11) reached genome-wide sig-
nificance (P < 5 × 10−8 Table 1). To assess the robustness of our results, the association analyses were also carried 
Figure 1. Exemplary photographs for a spectrum of clinical manifestations of chronic venous disease 
ranging from C1 to C6. (a) Spider veins, reticular veins; C1. (b) Varicose veins affecting the short saphenous 
vein; C2. (c) Edema due to varicose veins; C3. (d) Changes in skin and subcutaneous tissue, dermatosclerosis; 
C4. (e) Healed venous ulcer and Atrophie blanche; C5. (f) Active venous ulcer; C6. Photographs by courtesy of 
Dr. P. Krusche, Capio Mosel-Eifel-Clinic, Bad Bertrich.
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out with adjustments made for sex, age at ascertainment and body mass index (BMI). No notably different results 
were obtained in the sex-, age- and BMI-adjusted analyses (Supplementary Table 4).
When checking for potential coding SNPs being highly correlated (r2 > 0.8 in 1000 Genomes European 
samples) with the three lead SNPs (Methods), we identified only one further intronic SNP at the EFEMP1 and 
KCNH8 loci, respectively. At the SKAP2 locus 163 intronic variants, one 5’ UTR variant, five variants upstream 
and one variant downstream of SKAP2 correlate with the lead SNP. However, no coding variants in high LD were 
detected. 31 of these non-coding LD SNPs, all located at the SKAP2 locus on chromosome 7, were predicted to 
be deleterious by the fathmm11 algorithm (with values above 0.5), and 23 variants with a more stringent cutoff 
value above 0.8, respectively (Supplementary Table 5). The CADD12 method assigned scaled C scores of 10 or 
greater for 27 variants at the SKAP2 locus, indicating that these variants are among the highest 10% of all scores, 
whereas five variants were assigned a scaled C score above 15, a suggested cutoff value on the likelihood of delete-
riousness to identify potentially pathogenic variants (Supplementary Table 5). Of these five variants, four variants 
(rs10266759, rs3801828, rs3801808, rs3801814) had a fathmm score greater 0.8, strongly confirming their poten-
tial deleterious effect (Supplementary Table 5).
The intronic SNP rs17278665 at 2p16.1 maps to the last intron of the gene EFEMP1 (epidermal growth 
factor-containing, fibulin-like extracellular matrix protein 1; also known as FBNL), which encodes the extracel-
lular matrix protein fibulin-3. The association signal resides in a region of low linkage disequilibrium containing 
no other genes (Fig. 2a), pointing out the possibility of a direct involvement of EFEMP1 in disease development. 
The odds ratio for carriership of the minor risk allele G of rs17278665, as estimated from replication samples, was 
1.26 (95% CI = 1.13–1.41). The variant is a known local eQTL for EFEMP1 (PeQTL = 3.45 × 10−7 in lung tissue 
and PeQTL = 2.25 × 10−6 in skin)13,14 (Methods, Supplementary Table 6) with the minor allele being associated 
with decreased expression14 (Supplementary Figure 3a). Although classified as benign, the Mutation Taster15 
prediction tool reports the minor allele to increase a donor splice site and as a consequence, the potential loss of 
the protein region that mediates interaction with TIMP3, located partially downstream of the altered splice site 
(Supplementary Table 5). EFEMP1 is highly expressed in endothelial cells like Telomerase-immortalized micro-
vascular endothelial cells (RNA: 1866 FPKM, protein: 8931)16, human umbilical vein endothelial cells (HUVECs; 
7680 RPKM), human dermal blood endothelial cells (5896 RPKM) and human brain microvascular endothelial 
cells (4650 RPKM)17 (Supplementary Table 7). Data from the ENCODE17 and Roadmap Epigenomics18 projects 
imply that in HUVECs and mesenchymal tissue the variant overlaps with an HMM-predicted enhancer that is 
classified as a genic enhancer (15-state core model) and transcribed 3’ enhancer (25-state model), respectively 
(Supplementary Table 8).
The other genome-wide significantly associated SNP rs727139 at 3p24.3 (ORRepl1&2 = 0.75, 95% CI = 0.68–0.83) 
is located within the third intron of the KCNH8 gene without any other genes contained between the association 
boundaries (Fig. 2b). KCNH8 encodes a potassium voltage-gated channel. The Mutation Taster15 tool reports the 
minor allele of the variant to cause the generation of a new donor splice site, and the potential loss of several pro-
tein domains downstream of the altered splice site (Supplementary Table 5). According to the ENCODE17 data, 
KCNH8 is almost exclusively expressed in CD20+ B cells (13.1 RPKM) and embryonic stem cells (6.6 RPKM) 
Chr
Association 
boundaries 
(kb) dbSNP ida A1 A2 AFca AFco
Key gene (N 
additional 
in locus)
Discover GWAS 
(323/4,619)
Replication stage 1&2 
(1,946/3,146)
Discovery&Replication 
(2,269/7,765) Associations 
(P < 5 × 10−8) 
to other traitsP
OR  
(95% CI) P
OR  
(95% CI) P
OR  
(95% CI)
2p16.1 55979–56163 rs17278665 G C 0.17 0.15 EFEMP1 (0) 5.18 × 10−5 1.59  (1.28–1.98) 2.59 × 10
−5 1.26 
(1.13–1.41) 1.74 × 10
−8 1.32 
(1.19–1.45) H, O, FVC
3p24.3 19121–19548 rs727139 G A 0.16 0.21 KCNH8 (0) 1.69 × 10−4 0.63  (0.50–0.80) 3.39 × 10
−8 0.75 
(0.68–0.83) 5.42 × 10
−11 0.73 
(0.66–0.80) —
7p15.2 26657–27190 rs2030136 C T 0.26 0.24 SKAP2 (9) 3.93 × 10−4 1.48  (1.20–1.83) 6.84 × 10
−5 1.21 
(1.10–1.33) 3.39 × 10
−7 1.25 
(1.15–1.36) T1D*, CD*
Table 1.  Loci with strongest evidence of association with CVD in combined sample. We used a significance 
level of 0.05/70 = 7.14 × 10−4 for the statistical association analysis in replication panels (panel B and C; 
Supplementary Table 1) based on Bonferroni correction. All three SNPs replicated. Loci 2p16.1 and 3p24.3 
are genome-wide significant risk loci (P < 5 × 10−8) for CVD. Chr: chromosome; Association boundaries 
(kb): association boundaries for each index SNP in kb (see Methods) with genomic positions retrieved from 
NCBI’s dbSNP build v138 (genome build hg19); dbSNP id: rs ID of index SNP; A1: minor allele; A2: major 
allele; AFca/AFco: allele frequency of A1 estimated from replication stage1&2 (panel B-C) in cases and controls, 
respectively; Key gene: candidate gene in the region; for 7p15.2, 10 genes are covered by association boundaries: 
C7orf71, HOTAIRM1, HOXA1, HOXA2, HOXA3, HOXA4, HOXA5, HOXA6, HOXA-AS3 and SKAP2. P and 
OR (95% CI): P-value and corresponding odds ratio and 95% confidence interval with respect to minor allele. 
For each panel, numbers of CVD cases/controls are displayed in parentheses. Associations (P < 5 × 10−8) 
to other traits: Overlaps with other disease phenotypes (listed if anywhere within association boundaries, 
* = known genome-wide significant risk SNP in perfect LD (r2 = |D′ | = 1) with CVD hit SNP, see also Methods): 
CD = Crohn’s disease (rs10486483), FVC = forced vital capacity (rs1430193), H = Height (rs1367226, 
rs3791679, rs3791675), O = optic disc morphology (rs1346786), T1D = Type 1 diabetes (rs7804356). aSNPs 
attaining genome-wide significance and their notable nearby genes are indicated in bold.
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(Supplementary Table 7). In the Roadmap Epigenomics18 data, there is a cluster of promoter and enhancer activity 
in embryonic stem cells and induced pluripotent stem cells (iPSCs) overlapping with the variant. The 15-state 
core model classified it as enhancer and flanking active transcription start site whereas the 25-state core model 
classified it as active enhancer. In addition, a DNase hypersensitivity data peak overlaps with rs727139 in iPSCs 
(Supplementary Table 8).
SNP rs2030136 is located within the third intron of the SKAP2 gene (src kinase associated phosphop-
rotein 2; 7p15.2) and showed highly significant association in the combined analysis (Pcombined = 3.39 × 10−7) 
(Fig. 2c). The gene product of SKAP2 is potentially involved in leukocyte adhesion processes and couples the 
B-cell receptor in B-cells to integrin activation19. According to the 1000 Genomes Project EUR reference20, SNP 
rs2030136 is in perfect LD (r2 = 1.0) with SNPs rs7804356 and rs10486483 that were previously reported to be 
associated with type I diabetes21 and Crohn’s disease22, respectively. SNP rs2030136 is a known local eQTL of 
SKAP2 (PeQTL = 4.99 × 10−141)23 and HOXA5 (PeQTL = 4.69 × 10−7)14 (Supplementary Table 6), a gene that blocks 
angiogenesis, with the minor allele being associated with increased expression (Supplementary Figure 3b). 
In addition, this SNP is in high LD (r2 > 0.8) with 168 other known eQTL SNPs for SKAP2 and HOXA5 
Figure 2. Regional association plots of loci with strongest evidence of association with CVD in combined 
sample. Shown are the negative log10 (genomic control adjusted) P-values from the discovery analysis of 323 
unrelated German CVD cases and 4,619 healthy control individuals (panel A, Supplementary Table 1) with 
regard to the physical location of markers. The intronic SNPs (a) rs17278665, (b) rs727139, and (c) rs2030136 
were genotyped in the two replication panels and therefore the combined P-value of panels A, B and C (PABC) 
is indicated for these three lead SNPs (purple diamond) in addition to the P-value of panel A (PA), whereas 
for the surrounding SNPs in each plot only the respective P-values of panel A are available. Loci 2p16.1 
and 3p24.3 are genome-wide significant risk loci (P < 5 × 10−8) in the combined analysis of discovery and 
replication stages (2,269 CVD cases and 7,765 controls). Purple circle: index SNP with P-value of panel A; 
Purple diamond: index SNP with combined P-value of panel A, B and C; filled circles: analyzed SNPs with the 
fill color corresponding to the strength of linkage disequilibrium (r2) with the lead SNP (for color coding see 
legend in the upper right corner of each plot); blue line: recombination intensity (cM/Mb); highlighted region: 
association boundaries for each index SNP (see Methods and Table 1). Positions and gene annotations are 
according to NCBI’s build 37 (hg19).
www.nature.com/scientificreports/
5SCienTifiC REPORTS | 7:45652 | DOI: 10.1038/srep45652
(Supplementary Table 6). Although SKAP2 is expressed ubiquitously in human tissues24, it is expressed stronger 
in human renal cortical epithelial cells (31 RPKM), lymphoblastoid cells (18 RPKM) and human dermal blood 
endothelial cells (17 RPKM) according to the ENCODE data (Supplementary Table 7).
Discussion
We performed to our knowledge the first genome-wide association study for CVD and identified three novel 
CVD susceptibility loci. The analysis of our combined sample of 2,296 CVD cases and 7,765 controls implicates 
genetic variants in the genes EFEMP1, KCNH8 and SKAP2 in CVD susceptibility for the first time. The gene 
product of EFEMP1, fibulin-3, is an extracellular matrix glycoprotein, and belongs to the six-member fibulin 
family. The protein family is phylogenetically conserved and shows a high conservation of orthologues among 
different species. A single missense mutation in the EFEMP1 gene causes the autosomal dominant maculopathy 
Malattia Leventinese/Doyne honeycomb retinal dystrophy in all patients and families so far reported25. Efemp1− 
/− mice showed reduced fertility, premature aging, had a reduced life span and other phenotypes. Histologic 
analysis of these mice revealed a marked reduction of elastic fibers in fascia throughout the body26 whereas mice 
that lack fibulin-1 die at birth from defects associated with endothelial cell abnormalities27. Fibulin-3 is most 
homologous to fibulin-4 and -5, but also shows a strong homology to members of the fibrillin family28. Mutations 
in fibulin-5 have been identified in patients with cutis laxa29,30 and mutations in fibrillin I cause Marfan syndrome, 
a disorder of connective tissue with manifestations involving the skeletal, ocular and cardiovascular systems31. 
There is evidence that fibulin-3 and -5 antagonize vessel development in vivo and fibulin-3 and -5 both repress 
the expression of the matrix metalloproteinases MMP-2 and MMP-3 while they induce the expression of the 
tissue inhibitors of metalloproteinases TIMP-1, TIMP-3 and TSP-1 in endothelial cells32. In varicose veins the 
expression of MMP1, -2, -3, -7, -9 and -13, and TIMP-1 and -3 is increased33–35. Both groups of enzymes (MMPs 
and TIMPs) regulate homoeostasis of the extracellular matrix with MMPs being involved in degradation of the 
extracellular matrix and TIMPs influencing vascular remodeling34,36. An imbalance between these proteins may 
lead to changes in the vessel wall and, eventually, to CVD. Because EFEMP1 is expressed in disease-relevant tissue 
(Supplementary Table 7), we hypothesize that genetic variation in EFEMP1 could influence the expression of 
certain MMPs and TIMPs which might result in defects in cellular and extracellular matrix components, causing 
an altered vein elasticity. However, fine-mapping studies are needed to identify the actual causal variant(s) and 
its/their functional consequence(s).
KCNH8 is a member of the human Elk K+ channel gene family. Voltage-gated potassium channels represent 
the most complex class of voltage-gated ion channels from both functional and structural standpoints. Their 
diverse known functions include regulating neurotransmitter release, heart rate, insulin secretion, neuronal excit-
ability, epithelial electrolyte transport and smooth muscle contraction. Interestingly, several studies have demon-
strated the involvement of ion channels in venous dilatation and varicose vein formation37. For example, Raffetto 
et al. described MMP-2 induced venous dilatation via hyperpolarization and activation of K+ channels. Among 
several possible mechanisms by which MMP-2 could activate K+ channels, they suggested that as a result of col-
lagen degradation by the protease activity of MMP-2, soluble Arg-Gly-Asp (RGD) tripeptide can bind to smooth 
muscle α vβ 3 integrin receptors and lead to activation of K+ channels, venous hyperpolarization and relaxation38. 
This is further supported by an observed partial inhibition of vasodilatation with inhibitors of voltage-gated, 
ATP-sensitive and inward rectifying K+ channels39. Whether the herein identified marker rs727139 is tagging 
causative variant(s) at the KCNH8 locus and what role the protein itself might play in disease etiology needs to be 
elucidated in the future.
The gene product of SKAP2 is an adaptor protein that is thought to be involved in the Src signaling pathway 
and to regulate proper activation of the immune system. Among its related super-pathways is “cell junction organ-
ization”. Variants at the SKAP2 gene locus have previously been implicated in type 1 diabetes40 and in Crohn’s dis-
ease22. SKAP2 is expressed broadly in lymphoid and myeloid cells and plays an adhesive/migratory role in B cells 
and dendritic cells. It interacts with the immune inhibitory receptor protein SIRPα (Signal Regulatory Protein-α ) 
and drives the transduction of integrin-evoked signals which cause cytoskeletal reorganization required for 
macrophage migration41. Skap2- and Sirpα -deficient mice are resistant to experimental autoimmune enceph-
alomyelitis and collagen-induced arthritis, two models for the human diseases multiple sclerosis and rheuma-
toid arthritis that have integrin-dependent components. These findings imply an important role for SKAP2 in 
inflammation, particularly in integrin-dependent and macrophage-centric processes like atherosclerosis and 
inflammatory bowel disease41. A key aspect of CVD is inflammation, particularly caused by macrophages and 
monocytes, resulting from persistently increased venous pressure which is sensed by the endothelial cells and fol-
lowed by recruitment of leukocytes, endothelial attachment, and finally, initiation of an inflammatory cascade42. 
Accordingly, SKAP2 is an interesting candidate gene for functional studies in CVD development. The minor allele 
of SNP rs2030136 is strongly associated with increased expression of SKAP2 and HOXA5. Furthermore, there are 
168 other known eQTL SNPs for SKAP2 and HOXA5 in high LD. HOXA5 is abundantly expressed in quiescent 
blood vessels, whereas its expression is diminished or absent in active angiogenic endothelial cells43. The HOXA5 
gene blocks angiogenesis by up-regulating expression of anti-angiogenic genes like Thrombospondin-2 and 
down-regulating many pro-angiogenic genes such as vascular endothelial growth factor receptor 2 (VEGFR2) and 
hypoxia inducible factor-1 alpha (HIF1α)43. VEGFR-2 mediates most of the known cellular responses to VEGF, 
which plays a central role in maintaining vascular integrity and reactivity. The proangiogenic cytokine VEGF and 
its upstream transcription factor HIF-1α are important for new vessel formation such as vasa vasora44,45.
Identification of genetic susceptibility factors in the etiology of chronic venous disease is fundamental for 
future translational and clinical research in order to understand disease mechanisms and to be able to translate 
knowledge of involved genes into better prevention and/or treatment of patients. The three risk variants newly 
identified here collectively account for 2.0% of the total variance in disease liability (heritability) for CVD, indi-
cating that more powerful GWAS studies including larger sample sets are required not only to confirm the herein 
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reported loci but to detect potential additional causal variants. Fine-mapping and resequencing efforts together 
with extensive functional studies may help to specify the contribution of the respective genes to overall disease 
susceptibility and to study the mechanisms that are altered through the risk variants.
Methods
Study population. To narrow down the wide spectrum of clinical severity of CVD, we included only patients 
with primary varicose veins with and without signs of edema and/or skin changes (C2-C4) but without healed 
or active venous ulcer (C5/C6). The prevalence of the different CVD grades (C2-C4) in the overall study popu-
lation is presented in Supplementary Table 9. Personal characteristics of the CVD patients and healthy control 
individuals can be found in Supplementary Tables 10 and 11, respectively. In all patients, the primary varicose 
veins affected the superficial great saphenous vein (vena saphena magna), frequently accompanied by additional 
varicosities of the short saphenous vein (vena saphena parva). Patients with any signs of acute deep vein thrombo-
sis were excluded. The samples were organized in panels that corresponded to the successive steps of the present 
study. All individual panels (A-C in Supplementary Table 1) were independent from each other. All patients were 
from Germany, recruited at the Capio Mosel-Eifel-Clinic (Bad Bertrich, Germany). Ascertainment criteria for 
CVD are based on the CEAP classification system, which was developed in 1994 and subsequently revised3. Its 
key elements are clinical severity, etiology or cause, anatomy and pathophysiology.
4,374 German healthy control individuals of panel A-C were obtained from the PopGen biobank46. 
3,391 German healthy controls of panel A were selected from the KORA S3 and S4 survey, an independent 
population-based sample from the general population living in the region of Augsburg in southern Germany47.
Genomic DNA was prepared from blood samples using the Invisorb Blood Giga Kit (Invitec, Berlin, 
Germany). All DNA samples were quality-checked on agarose gels.
Written, informed consent was obtained from all study participants and the Ethics Committee of the Medical 
Faculty of the CAU Kiel approved all protocols. All methods carried out were in accordance with the approved 
study protocols.
SNP genotyping for discovery sample and quality control. Genotyping of GWAS cases and PopGen 
controls - which was part of the German GWAS initiative funded by the National Genome Research Network 
(NGFN) - was performed as a service project by Affymetrix. All experimental steps were carried out according 
to standard protocols. SNPs that had > 5% missing data in cases or controls, a minor allele frequency < 1% or 
deviated from Hardy-Weinberg equilibrium (exact P < 10−4 in controls) were excluded using the PLINK soft-
ware version 1.0748. We excluded individuals with more than 5% missing genotypes (i.e. call rate < 95%), indi-
viduals from each pair of unexpected duplicates or relatives, as well as outlier individuals with average marker 
heterozygosities of ± 5 s.d. away from the sample mean. Pair-wise percentage identity-by-state (IBS) values were 
computed for all individuals and all QCed markers using PLINK. ‘Extreme outliers’ were detected by comparing 
the distribution of the pair-wise IBS values for each individual with the combined IBS distribution of the entire 
study population. Two types of “outliers” were detected: 1) Individuals less related to the entire study population 
than expected were defined as those for whom > 60% of the IBS values were smaller than the median minus three 
times the interquartile range (3 × IQR) of the population distribution. In this case, the individual was removed 
from the population. 2) Individuals with a close cognate (relative) in the population were defined as those who 
had at least one observed IBS value above the median plus 3 × IQR. In this case, the member of the cognate pair 
with the lower call rate was removed from the population. ‘Extreme outliers’ were calculated using R 2.15.249.
These quality control measures left genotype data of a set of 302,457 autosomal overlapping SNPs in 323 
CVD samples and 4,619 control samples for inclusion in the discovery phase (panel A, Supplementary Table 1). 
These samples were tested for population stratification using the principal components stratification 
method, as implemented in EIGENSTRAT50. Principal component analysis revealed no population outliers 
(Supplementary Figure 1).
Genome-wide genotype imputation and association analysis. As input for the imputation only 
genotyped SNPs that passed quality control were used. SNP genotype imputation was performed using the 
MACH version 1.10.1651 and 690 HapMap3 reference haplotypes from the CEU, TSI, MXL and GIH52 as well 
as 120 HapMap II CEU phased haplotypes cohorts to predict missing autosomal genotypes in-silico53. Including 
samples from diverse populations such as Mexican (MXL) and Indian (GIH) can provide significant improve-
ment in imputation for low-frequency variants (MAF < 5%)54. For downstream analyses, we included only SNPs 
that were imputed with high confidence (estimated r2 between imputed and true genotypes > 0.8) and had a 
MAF ≥ 1%. We further excluded markers deviating from HWE in controls after imputation (P < 10−6). In total, 
1,934,349 quality-controlled autosomal genotyped or imputed SNP markers were available for association anal-
ysis (Supplementary Figure 2). To take imputation uncertainty into account, phenotypic association was tested 
for allele dosage data using MACH2DAT’s logistic regression framework for dosage data51. The allelic dosage is 
the weighted sum of the genotype class probabilities. To control potentially confounding effects due to popula-
tion stratification, we adjusted for the top five eigenvectors (indicating statistical significance by Tracy-Widom 
statistics) from EIGENSTRAT in the regression analysis. In addition, genomic control correction was applied to 
results by correction of χ 2 test statistics using inflation factor λ = 1.156 and multiplying SNP standard errors by 
the square root of the inflation factor in order to minimize artificial differences in allele frequencies due to differ-
ent genotyping platforms (see quantile-quantile plot in Supplementary Figure 4).
Replication genotyping. Since only a few variants showed a substantial deviation from the expected dis-
tribution of genome-wide P-values in the tail of the distribution, we genotyped in stage one the 70 most strongly 
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associated SNPs with P < 10−3 from each associated locus by means of PLINK’s clumping procedure (using set-
tings P1 < 0.001, P2 < 0.05, r2 ≥ 0.8, kb = 250) in an independent German panel of 1,258 CVD cases and 1,925 
control individuals (panel B; Supplementary Table 1), using the Sequenom® iPlex platform and TaqMan® tech-
nology from Life Technologies. Adjustment for multiple testing was performed by Bonferroni correction for 70 
SNPs (association results of 70 SNPs; Supplementary Table 2). In stage two, we selected 3 SNPs that replicated 
at P < 0.05/70 = 7.14 × 10−4 in stage one for TaqMan® genotyping in an additional German panel comprising 
688 CVD cases and 1,221 control individuals (panel C; Supplementary Table 1, association results of 3 SNPs; 
Supplementary Table 3). Individual samples with > 5% missing data were excluded from the downstream anal-
yses. SNPs that had > 3% missing data or deviated from Hardy-Weinberg equilibrium (exact P < 10−4 in con-
trols) were excluded. P-values for allele-based tests were calculated using PLINK. The fixed-effects meta-analysis 
function of PLINK was then used to obtain P-values for the combined replication data set (panel B-C) and the 
combined discovery-replication data set (panel A-C). We used the commonly accepted threshold of 5 × 10−8 for 
joint P-values to define genome-wide significance.
Annotation of association boundaries & regional association plots. Linkage disequilibrium 
regions (association boundaries) around lead SNPs from Table 1 were defined by extending in both directions a 
distance of 0.1 centimorgans (cM). For each locus, candidate genes within regions are listed in the column ‘Key 
gene’ and more details are listed in the legend of Table 1. Regional association plots of Fig. 2 were generated using 
Locuszoom55.
Annotation of associations to other phenotypes. Overlaps with other phenotypes were annotated 
with the NHGRI GWAS-catalog56 (http://www.genome.gov/gwastudies/, date of access Dec-1-2015). All known 
associations with P < 5 × 10−8 with any disease or primary phenotype were included. For each susceptibility locus 
with association boundaries defined in Table 1, we annotated all phenotypes that had at least one associated SNP 
within the region. We also checked whether the hit SNP in the NHGRI GWAS catalogue was the same as, or in 
high LD with (r2 > 0.8) the CVD lead SNP.
Functional annotation of associated variants. All SNPs in high LD (r2 > 0.8) with the three lead var-
iants at CVD associated loci were identified using the SNP Annotation and Proxy Search57 (SNAP) online tool 
(version 2.2; https://www.broadinstitute.org/mpg/snap/index.php). The three non-coding lead SNPs and all 
variants in high LD (171 non-coding SNPs) were annotated using the following online tools that aim to pre-
dict the functional impact of non-coding sequence variants by obtaining information about sequence conserva-
tion (conservation metrics like GERP, phastCons and phyloP), chromatin state and protein binding annotation 
from the Roadmap Epigenomics18 and ENCODE17 projects, the effect of SNPs on regulatory motifs, on expres-
sion from eQTL studies and on splice sites (Supplementary Tables 5, 6, 8): Combined Annotation-Dependent 
Depletion (CADD)12 v1.3 (GRCh37/hg19; http://cadd.gs.washington.edu/home), fathmm11 v2.3 (http://fathmm.
biocompute.org.uk/index.html), MutationTaster15 (NCBI build 37, Ensemble 69; http://www.mutationtaster.org) 
and HaploReg58 v4.1 (http://www.broadinstitute.org/mammals/haploreg/haploreg.php). The tool CADD uses 
the Ensembl Variant Effect Predictor (VEP59), data from the ENCODE17 project and information from UCSC 
genome browser tracks for annotation. The output of MutationTaster includes ‘regulatory features’ like histone 
modification sites, open chromatin or transcription factor binding sites from the Ensembl Regulation database 
(http://www.ensembl.org/info/genome/funcgen/index.html) and ‘splice sites’ to show possible changes in splice 
sites using the locally installed third party splice site prediction program NNSplice60. For the ‘splice site’ results, 
MutationTaster determines the position of the splice site change (increased/decreased or gained/lost splice site) 
relative to intron/exon borders. Only a loss/decrease of a splice site that occurs at an intron/exon (or reverse) 
border is shown, whereas such a change distant from any intron/exon border is ignored. For a significant finding 
the confidence score for the gain of a new splice site has to be greater than 0.3 and for an increase in an existing 
splice site greater than 10%. The online tool HaploReg annotates variants by their effect on regulatory motifs by 
using a library of position weight matrices collected from TRANSFAC, JASPAR, protein-binding microarray 
and ENCODE ChIP-seq experiments61 and extracts functional annotations from the ENCODE17 and Roadmap 
Epigenomics18 projects, including a chromatin 15-state and 25-state core model learned on five and 12 core chro-
matin marks, respectively. The chromatin state learning was performed to capture significant combinatorial inter-
actions between different chromatin marks in their spatial context with a tool based on a multivariate Hidden 
Markov Model (HMM)18
Expression quantitative trait loci (eQTL). eQTL data was obtained from the genotype-tissue expres-
sion (GTEx) project14 (http://www.gtexportal.org/), the GEUVADIS62 data browser (http://www.ebi.ac.uk/Tools/
geuvadis-das/) and 11 other studies using HaploReg58 v4.1 (see Supplementary Table 6).
Gene expression. Information about EFEMP1, KCNH8 and SKAP2 gene expression (Supplementary Table 7) 
was obtained from the publicly available database THE HUMAN PROTEIN ATLAS16 (http://www.proteinatlas.
org/) and the ENCODE17 expression data (http://promoter.bx.psu.edu/ENCODE/search_human.php). THE 
HUMAN PROTEIN ATLAS16 provides quantitative data on gene expression levels (RNA expression in fragments 
per kilobase of exon model per million mapped reads (FPKM) and protein expression as antibody staining inten-
sity with values from 0 to 9000) for 46 different human cell lines and 44 human tissues. The ENCODE17 project 
provides gene expression data of 58 human cell types consisting of 108 datasets (RNA expression in reads per 
kilobase per million mapped reads (RPKM)).
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Variance explained and heritability of single SNPs. The proportion of variance explained by each 
association signal per population was calculated using a liability threshold model63 assuming a disease prevalence 
of 0.313 for CVD and log-additive disease risk from replication stage1&2 samples (panel B-C).
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